由Adis International Limited（現(xiàn)為Wolters Kluwer Health的一部分）出版。國際標(biāo)準(zhǔn)書號(hào)：1177-1062。結(jié)合分子診斷的前沿內(nèi)容和美國藥物基因組學(xué)雜志，分子診斷和治療為您帶來了獨(dú)立和權(quán)威的見解，最新的分子診斷和藥物基因組技術(shù)，以提高患者的疾病診斷和治療的個(gè)性化方式。聯(lián)合期刊提供了更全面的見解：使用生物標(biāo)志物指導(dǎo)藥物開發(fā)，作為診斷手段，并針對特定人群定位藥物；檢測、監(jiān)測和治療疾病的分子原因；影響藥物反應(yīng)、藥物代謝、不良反應(yīng)的分子標(biāo)志物和遺傳變異。和/或疾病進(jìn)展；分子疾病分類；藥物/診斷組合（治療學(xué)）；新興的分子診斷工具和技術(shù)；病原體檢測和耐藥性分析；與個(gè)性化醫(yī)學(xué)有關(guān)的倫理和監(jiān)管問題。

Published by Adis International Limited (now part of Wolters Kluwer Health). ISSN: 1177-1062.Combining the cutting-edge content of Molecular Diagnosis and the American Journal of Pharmacogenomics, Molecular Diagnosis & Therapy brings you independent and authoritative insights into the latest molecular diagnostic and pharmacogenomic techniques to improve the diagnosis and treatment of disease in patients in an individualized manner. The combined journal provides more comprehensive insight into: Using biomarkers to guide drug development, serve as diagnostics, and target medicines toward specific populations; Detection, monitoring and treatment of the molecular causes of disease; Molecular markers and genetic variation affecting drug response, drug metabolism, adverse effects and/or disease progression; Molecular disease classification; Drug/diagnostic combinations (theranostics); Emerging molecular diagnostic tools and technologies; Pathogen detection and drug resistance analysis; Ethical and regulatory issues relating to personalized medicine.